- Scoring System to Distinguish L1 and L2 Variants
- Prognostic Factors in Adult ALL
- Prognostic Factors in Childhood ALL
- Prognostic Factors in Children with Philadelphia Chromosome Positive ALL
- Prognostic Model of Den Boer et al for a Patient with Acute Lymphoblastic Leukemia Based on Chemotherapy Resistance Profiles
- Grading Scheme of Kurtzberg et al for Measuring Response to Chemotherapy in Acute Leukemia
- National Cancer Institute (NCI) Risk Categories for a Child with Acute Lymphoblastic Leukemia (ALL)
- Risk Factors of Sancho et al for Central Nervous System Involvement in a Patient with Acute Lymphoblastic Leukemia
- Prognostic Factors of Oudot et al for a Child with Acute Lymphoblastic Leukemia Who Fails Induction Therapy
- Clinical Features of Acute Lymphoblastic Leukemia (ALL) in a Patient with Down's Syndrome (Trisomy 21)
- Prognostic Factors of O'Brien et al for an Adult with Acute Lymphocytic Leukemia (ALL) Following Second Salvage Therapy
- Reasons for Suspecting Leukemia in a Child
- Acute and Aggressive Subtype of Adult T-Cell Leukemia/Lymphoma Associated with HTLV-1
- Prognostic Factors of Kantarjian et al for an Adult with Acute Lymphocytic Leukemia (ALL) After First Salvage Therapy
- Modified European Group for Blood and Marrow Transplantation Risk Score (mEBMT) of Terwey et al for an Adult with Acute Lymphoblastic Leukemia
- Prognostic Groups of Phillips et al for HTLV-1 Associated Adult T-Cell Leukemia/Lymphoma
- Prognostic Factors of Schrappe et al for a Pediatric Patient with Acute Lymphoblastic Leukemia (ALL) After Induction Failure
- Morphologic Criteria of Schrappe et al for Failure of Induction Therapy for a Patient with Acute Lymphoblastic Leukemia (ALL)
- Monitorng L-Asparagine Depletion or L-Asparaginase Activity in a Patient with Acute Lymphoblastic Leukemia (ALL)
- Prognostic Index of Katsuya et al for a Patient with Acute and Lymphoma Types of Adult T-Cell Leukemia/Lymphoma (ATL-PI)
- Clinical Subtypes of Adult T-Cell Leukemia/Lymphoma (ATLL)
- Binet Staging System for Chronic Lymphocytic Leukemia (CLL)
- Rai Staging System for Chronic Lymphocytic Leukemia (CLL)
- Hairy Cell Leukemia and the Hairy-Cell Index
- Criteria for Smoldering Chronic Lymphocytic Leukemia (CLL) and Lymphocyte Doubling Time
- Criteria of the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) for Response to Therapy in CLL
- Criteria of the National Cancer Institute (NCI) Working Group for Response to Therapy in B-Cell CLL
- Criteria for "Active" Chronic Lymphocytic Leukemia (CLL) and the Need for Therapeutic Intervention
- Indications for Splenectomy in Chronic Lymphocytic Leukemia
- Richter's Syndrome
- Use of ZAP-70 and Immunoglobulin Heavy Chain Gene Mutation Status to Predict Therapy Free Survival in a Patient with Chronic Lymphocytic Leukemia
- Richter Syndrome (RS) Score of Tsimberidou et al
- Clinical and Laboratory Findings in Hairy Cell Leukemia
- Criteria of Marti et al for Monoclonal B-Cell Lymphocytosis
- Use of Abdominal CT to Evaluate a Patient with Rai Stage 0 CLL
- Simplified Risk Group Assignment of Lee et al for a Patient with Chronic Lymphocytic Leukemia (CLL)
- Prognostic Score of Tsimberidou et al for a Patient with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (University of Texas M.D. Anderson Cancer Center Score)
- Correlating the Response to Rituximab Therapy for a Patient with Chronic Lymphocytic Leukemia (CLL) with the FISH Subtype
- Risk Factors of Nowakowski et al Affecting Survival in a Patient with Chronic Lymphocytic Leukemia (CLL)
- Prognostic Index of Wierda et al for a Patient with Chronic Lymphocytic Leukemia (CLL)
- Therapy Independent Nomogram of Wierda et al for Evaluating a Previously Untreated Patient with Chronic Lymphocytic Leukemia (CLL)
- Therapy Inclusive Nomogram of Wierda et al for Evaluating a Previously Untreated Patient with Chronic Lymphocytic Leukemia (CLL)
- Prognostic Classification of Dighiero and Hamblin for Chronic Lymphocytic Leukemia
- Risk Factors of Francis et al for Major Infections in a Patient with Chronic Lymphocytic Leukemia (CLL)
- Indolent Mantle Cell Leukemia
- Model of Wierda et al for Time to First Treatment in a Patient with Chronic Lymphocytic Leukemia (CLL)
- Scoring System of Matutes et al for Immunophenotyping Hairy Cell Leukemia (HCL)
- Bone Marrow Fibrosis in a Patient with Chronic Lymphocytic Leukemia (CLL)
- Chronic Lymphocytic Leukemia with Prolymphocytoid Transformation (CLL/PL)
- Findings Associated with a Poor Prognosis in a Patient with Chronic Lymphocytic Leukemia (CLL)
- Algorithm of Siddon et al for Treating a Patient with CLL
- Prognostic Factors of Nowakowski et al for a Patient with Chronic Lymphocytic Leukemia (CLL)
- Prognostic Factors in Acute Myeloid Leukemia
- French-American-British (FAB) Classification of Acute Myeloid Leukemia
- Subclassification of Erythroleukemia
- Prognostic Groups of Estey for Acute Myelogenous Leukemia (AML)
- Distinguishing Acute Promyelocytic Leukemia (APML) from the Recovery Phase of Acute Agranulocytosis Using CD117 and CD11b Immunostaining of the Bone Marrow
- Prognostic Index of Breems et al (European Prognostic Score) for an Adult Patient with Acute Myelogenous Leukemia (AML) in the First Relapse
- Risk Groups of Giles et al in Patients with Acute Myelogenous Leukemia After Second Salvage Therapy
- Mortality Risk Factors of Creutzig et al in Children Treated for Acute Myeloid Leukemia (AML) in the Berlin-Frankfurt-Muenster (BFM) Trials 93 and 98
- Prognostic Score of Jourdan et al for a Young Adult with Acute Myeloblastic Leukemia in First Complete Remission and without a Donor for Allogeneic Stem Cell Transplantation
- Risk Factors of Johnston et al for an Isolated CNS Relapse in a Pediatric Patient with Acute Myeloid Leukemia
- Risk Factors for the Development of Acute Myeloid Leukemia
- Model of Kantarjain et al for Predicting Complete Response in a Patient >= 65 Years Old Treated with Intensive Chemotherapy for Acute Myelogenous Leukemia or High-Risk Myelodysplastic Syndrome
- Model of Kantarjain et al for Predicting Induction Mortality and Overall Survival in a Patient >= 65 Years Old Treated with Intensive Chemotherapy for Acute Myelogenous Leukemia or High-Risk Myelodysp
- Prognostic Factors of Razzouk et al for a Child with Acute Myeloid Leukemia (AML)
- Model of Johnson et al for Predicting Survival for an Elderly Patient with Acute Myeloid Leukemia (AML)
- Model of Estey et al for Predicting Survival During Induction Therapy in a Patient Newly Diagnosed with Acute Myeloblastic Leukemia (AML)
- Prognostic Factors of Rubnitz et al for a Pediatric Patient with Recurrent Acute Myeloid Leukemia
- Prognostic Factors of Etienne et al for Complete Remission in an Elderly Patient Receiving Induction Chemotherapy for Acute Myeloid Leukemia (AML)
- Auer Rods versus Pseudo-Auer Rods
- Risk Model of Sorror et al for a Patient with Acute Myeloid Leukemia or Myelodysplasia Following Allogeneic Hematopoietic Cell Transplantation
- Clinical and Laboratory Features of the Microgranular or Hypogranular Variant of Acute Promyelocytic Leukemia (M3v)
- Prognostic Score of Haferlach et al for Acute Myeloid Leukemia (AML)
- Model of Sanz et al for Risk of Relapse in a Patient with Acute Promyelocytic Leukemia
- Prognostic Factors of Harb et al for a Patient Greater Than or Equal to 80 Years of Age with Acute Myeloid Leukemia
- Immunohistochemical Algorithm of Cronin et al for Diagnosis of Myeloid Leukemia Cutis
- Acute Myeloid Leukemia in a Patient with Down's Syndrome (Trisomy 21)
- Activity of the Renin-Angiotensin System (RAS) in Acute Myeloid Leukemia
- Prognostic Factors of Knipp et al for a Patient More Than 60 Years of Age with Acute Myeloid Leukemia or Myelodysplasia
- Response Criteria Following Therapy of Acute Myeloid Leukemia (AML)
- Criteria for Relapse of Acute Myeloid Leukemia (AML) Following Remission
- Impact of Age and DNMT3A Mutation Status on Survival for a Patient with Acute Myeloid Leukemia (AML)
- Acute Myeloid Leukemia (AML) with Cytogenetic Abnormalities at 3q21q26
- Prognostic Factors of Kurosawa et al Affecting Survival for a Patient with Acute Myeloid Leukemia (AML) After First Relapse
- Scoring System of Valcarcel et al for Predicting Death During Induction Therapy for Acute Myelogenous Leukemia (AML)
- Basic Model of Walter et al for Predicting Early Death After Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia (AML)
- Complex Model of Walter et al for Predicting Early Death After Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia (AML)
- Prognostic Score of Malagola et al for Cytogenetically Normal Acute Myeloid Leukemia (CN-AML)
- Risk Factors of Mailankody et al for Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Occurring in a Patient with Multiple Myeloma or Monoclonal Gammopathy of Unknown Significance (MGUS)
- Criteria of de Greef et al for Complete Remission in Acute Myeloid Leukemia (AML)
- Features of Immunomodulator Agent-Related Lymphoproliferative Disorders Reported By Hasserjian et al
- Methotrexate-Associated Lymphoproliferative Disorder
- Phenytoin-Induced Pseudolymphoma
- Lymphoma Associated with Phenytoin Therapy (Pseudo-Pseudolymphoma)
- Diagnosis of Monoclonal Gammopathies
- Myeloma Staging System of Durie and Salmon
- Myeloma Staging System of Carbone et al
- Myeloma Staging System of British Medical Research Council
- Myeloma Staging System of Alexanian et al
- Myeloma Staging System of Southeastern Cancer Study Group
- Myeloma Staging System of ALGB and ECOG
- Criteria for the POEMS Syndrome
- Myeloma Staging System of Pasqualetti et al
- Criteria of the Chronic Leukemia-Myeloma Task Force for Evaluating the Response of Multiple Myeloma to Therapy
- Myeloma Staging System of Durie and Salmon Supplemented with MRI
- International Staging System of the International Myeloma Working Group (Greipp et al) for Multiple Myeloma
- Prognostic Factors of Weber et al for Progression in Asymptomatic Multiple Myeloma
- Risk Stratification Model of Weber et al Predicting Progression in Asymptomatic (Smoldering) Multiple Myeloma
- Prognostic Factors of Rajkumar et al for Progression in a Patient with Monoclonal Gammopathy of Undetermined Significance (MGUS)
- Features of Solitary Plasmacytoma
- Staging System of the Southwest Oncology Group (SWOG) for a Patient with Multiple Myeloma
- Diagnostic Algorithm of Shaw for Nonsecretory Plasma Cell Myeloma
- Prognostic Groups of Kyle et al for Patients with Smoldering (Asymptomatic) Multiple Myeloma
- Hyperammonemia in a Patient with Multiple Myeloma
- Prognostic Factors of Hillengass et al for a Patient with Asymptomatic Multiple Myelomas, Including Focal Lesions in Bone Detected by Whole Body MRI
- Bone Marrow Staging System of Allawadhi et al for Multiple Myeloma Based on MRI Involvement (BM-MRI)
- Plasma Cell Leukemia
- Multiple Myeloma: Beta-2 Microglobulin and Serum Albumin
- Multiple Myeloma: Telopeptide
- Multiple Myeloma: Labelling Index (LI)
- Multivariate Analysis with Plasma Cell Morphology
- Histologic Grading of Plasma Cell Dysplasia in Multiple Myeloma
- Molecular Markers Used at the Mayo Clinic to Identify High-Risk Multiple Myeloma
- Criteria of Greipp et al for Myeloma Cell Typing and Myeloma Classification
- Light Chain Monoclonal Gammopathy of Undetermined Significance (LC-MGUS)
- Significance of Immunostaining a Bone Marrow Biospy Containing Plasma Cells with CD56 (NCAM)
- Model of Rossi et al for Predicting the Risk of Progression in a Patient with Asymptomatic Multiple Myeloma
- The TEMPI Syndrome
- Crystalglobulinemia Syndrome (Crystal-Induced Vasculopathy in Multiple Myeloma)
- Model of Schaefer et al for Correlating Prognosis with the Reduction in Serum Monocloncal Protein During Chemotherapy
- Staging System of Dispenzieri et al for Primary Systemic Amyloidosis Based on Cardiac Troponin and pro-BNP Serum Levels
- Risk Score of Dispenzieri et al for Primary Systemic Amyloidosis
- Unfavorable Prognostic Factors of Kyle et al for a Patient with Primary Amyloidosis
- Prognostic Factors of Moreau et al for Survival After Autologous Stem Cell Transplantation of a Patient with Systemic AL Amyloidosis
- Risk Groups of Kyle et al for Survival in Patients with Primary Systemic Amyloidosis
- Criteria of Gertz et al for Therapeutic Response in a Patient with Primary Systemic Amyloidosis
- Criteria of Kyle et al for Therapeutic Response in a Patient with Primary Systemic Amyloidosis
- Clinical Findings That Should Alert the Clinician to the Possibility of Amyloidosis
- Early Mortality Risk Score of Kumar et al for a Patient with Primary Systemic Amyloidosis
- Clinical Features of Dialysis-Associated Amyloidosis (Beta-2 Microglobulin Amyloidosis)
- Revised Prognostic Staging System of Kumar et al for a Patient with Light Chain (Primary Systemic) Amyloidosis
- Ann Arbor Stages of Non-Hodgkin's Lymphoma (Including B Symptoms)
- Histologic Grading of Follicular Lymphomas
- Prognostic Factors in Aggressive Malignant Lymphomas
- International Prognostic Index (IPI) and Prognosis in Aggressive Non-Hodgkin's Lymphoma
- Prognosis in Intermediate and High Grade Non-Hodgkin's Lymphoma
- Prognostic Factors in Aggressive Diffuse Non-Hodgkin's Lymphoma Before Therapy
- Risk Classification of Velasquez et al for Clinical Staging of Diffuse Large Cell Lymphoma
- Serologic Staging System for Diffuse Large Cell Non-Hodgkin's Lymphoma Using Initial Serum Lactate Dehydrogenase and beta-2-Microglobulin Levels
- Prognostic Model of Federico et al for Follicular Lymphoma (Italian Lymphoma Intergroup Index)
- The University of Texas M.D. Anderson Cancer Center's Tumor Score for Aggressive Lymphoma
- Prognostic Factors of Wilder et al for Patients with Aggressive Lymphoma
- Memorial Sloan Kettering Cancer Center Predictive Model for Advanced Diffuse Histiocytic Lymphoma
- Prognostic Subgroups of Shipp et al for Diffuse Large Cell Lymphoma
- 1976 SWOG Criteria for Response of Non-Hodgkins Malignant Lymphoma to Therapy
- St. Jude Staging System for Burkitt's Lymphoma (Murphy Staging System)
- Prognostic Factors in Burkitt's Lymphoma
- Diagnostic Features of Microvillous Lymphomas
- Prognostic Score of Ferreri et al for Primary CNS Lymphoma (IELSG Score)
- Prognostic Factors of Dumontet et al for Death During Induction Chemotherapy in Patients with Aggressive Non-Hodgkin's Lymphoma
- Prognostic Factors of Arcaini et al for Survival in Patients with Marginal Zone Lymphomas
- Prognostic Factors of International Extranodual Lymphoma Study Group (IELSG) al for a Male with Diffuse Large Cell Lymphoma of the Testis
- Prognostic Factors of Chacon et al for Patients with Splenic Marginal Zone Lymphoma
- Criteria of Chacon et al for Therapeutic Response in Patients with Splenic Marginal Zone Lymphoma
- Prognostic Model of Lossos et al in Diffuse Large B-Cell Non-Hodgkin's Lymphoma Using a Panel of 6 Genes
- Criteria of Loggins and Urquhart for Suspecting Non-Hodgkin's Lymphoma in a Patient With a Parotid Mass
- Risk Factors of Stebbing et al for Non-Hodgkin's Lymphoma in a Patient with HIV Infection
- Standardized Response Criteria of Cheson et al for Therapy in Non-Hodgkin's Lymphoma
- Prognostic Factors of Mournier et al from the Groupe d'Etuda des Lymphomes de l'Adulte (GELA) for Patients with Aggressive Non-Hodgkin's Lymphoma Treated by Autologous Stem Cell Transplantation (ASCT)
- Risk Factors of Voulgarelis and Moutsopoulos for Development of Malignant Lymphoma in a Patient with Sjogren's Syndrome
- Criteria for T-Cell Rich, Histiocyte Rich Diffuse Large B-Cell Non-Hodgkin's Lymphoma
- Prognostic Factors of Shenkier et al for an Immunocompetent Patient with a Primary Central Nervous System Lymphoma
- Prognostic Factors of Shenkier et al for a Patient with a Primary T Cell Central Nervous System Lymphoma
- The Follicular Lymphoma International Prognostic Index (FLIPI)
- Immunophenotypic Markers of Berglund et al Associated with Prognosis for a Patient with Diffuse Large B-Cell Lymphoma
- Prognostic Factors of Hui et al for a Patient with Mantle Cell Lymphoma
- Prognostic Factors of Suzuki et al for a Patient with Blastic Natural Killer Cell (NK-Cell) Lymphoma/Leukemia
- Diagnostic Features of Blastic Natural Killer Cell (NK-Cell) Lymphoma/Leukemia
- Criteria of Boulanger et al for the Diagnosis of a Primary Effusion Lymphoma Associated with Human Herpesvirus 8 (HHV-8)
- Prognostic Factors of Boulanger et al for AIDS-Associated Primary Effusion Lymphoma (PEL)
- Risk Factors of Lyman et al for the Failure to Adequately Treat a Patient with an Aggressive Non-Hodgkin's Lymphoma
- Clinical Features of Intravascular Anaplastic Large Cell Malignant Lymphoma
- Prognostic Model of Lee et al for Extranodal Natural Killer/T (NK/T) Cell Lymphoma of the Nasal Type (Korean Prognostic Index, KPI)
- Guidelines of the International Primary CNS Lymphoma Collaborative Group for Therapeutic Response
- Clinical-Pathologic Prognostic Score of Went et al for a Patient with Peripheral T-Cell Lymphoma
- Prognostic Model of Gallamini et al for a Patient with a Peripheral T-Cell Lymphoma Unspecified (PTCL-U)
- Prognostic Model of Hoskins et al for a Patient with Diffuse Large Cell Lymphoma Treated with MACOP-B
- Risk Factors of Smedby et al for Malignant Non-Hodgkin Lymphoma in a Patient with Rheumatoid Arthritis
- Prognostic Factors of Lim et al for HIV-Related Diffuse Large-Cell Non-Hodgkin's Lymphoma
- Prognostic Model of Arcaini et al for a Splenic Marginal Zone Lymphoma (Intergruppo Italiano Linfomi Score)
- Prognostic Factors of Parry-Jones et al for Splenic Lymphoma with Villous Lymphocytes
- Prognostic Model of Low et al for a Patient with Grade II Non-Hodgkin's Lymphoma
- Criteria of Quintanilla-Martinez for Fulminant Epstein-Barr Virus (EBV) Positive T-Cell Lymphoproliferative Disorder
- Memorial Sloan-Kettering Cancer Center (MSKCC) Prognostic Model for Primary CNS Lymphoma
- Nottingham/Barcelona Prediction Score for Primary Non-Hodgkin's Lymphoma of the CNS
- Prognostic Factors of Laskar et al for a Patient with Primary Diffuse Large B-Cell Lymphoma of the Tonsil
- Criteria of Solal-Celigny et an for High Tumor Burden in a Patient with Malignant Non-Hodgkin's Lymphoma
- Colorectal Lymphomatous Polyposis
- Cytologic Variants of Mantle Cell Lymphoma
- Prognostic Factors of Bosch et al for a Patient with Mantle Cell Lymphoma
- Clinical Features of Lymphomatosis Cerebri
- Prognostic Factors of the International T-Cell Lymphoma Project for Peripheral T and NK/T Cell Lymphomas
- Prognostic Factors of Savage et al for a Patient with an NK/ T-Cell ALK+ Anaplastic Large-Cell Lymphoma (ALCL)
- Prognostic Factors of Savage et al for a Patient with an NK/ T-Cell ALK-Negative Anaplastic Large-Cell Lymphoma (ALCL)
- When to Consider the Diagnosis of Malignant Lymphoma in a Patient
- Clinical Features of Neurolymphomatosis
- Factors of Quijano et al Predictive of Leptomeningeal Disease in a Patient with Burkitt’s Lymphoma
- Follicular Lymphoma International Prognostic Index 2 (FLIPI2)
- Prognostic Genetic Markers of Cady et al for a Primary Central Nervous System (CNS) Lymphoma
- Intravascular Large B-Cell Non-Hodgkin's Malignant Lymphoma Presenting as Pulmonary Arterial Hypertension (PAH)
- Clinical Features of EBV-Related X-Linked Lymphoproliferative Disease (XLP)
- Prognostic Scoring System of Mazloom et al for a Patient with Extranodal Marginal Zone Lymphoma (MZL)
- Clinical and Pathological Features of Pyothorax-Associated Lymphoma (PAL)
- Clinical and Pathological Features of a Chronic-Inflammation Associated Lymphoma
- Risk of AIDS-Related Malignant Lymphoma in a Patient Based on Serum Free Light Chain Concentrations
- Chromosomal Abnormalities of Onciu et al Seen in Patients with Burkitt's Lymphoma
- Mantle Cell Lymphoma (MCL) International Prognostic Index (MIPI) of Hoster et al
- Significance of Lymphocytosis for a Patient with Mantle Cell Lymphoma
- Prognostic Factors of Weisenburger et al for a Patient with a Peripheral T-Cell Lymphoma Not Otherwise Specified (PTCL-NOS)
- Risk Factors of Cairo et al for Treatment Failure in a Pediatric Patient with a Mature B-Cell Non-Hodgkin’s Lymphoma
- Risk Groups of the Berlin-Frankfurt-Munster (BFM) Group for Burkitt Lymphoma
- When to Consider the Diagnosis of EBV-Positive Diffuse Large B Cell Lymphoma of the Elderly versus Classic Hodgkin's Disease
- Prognostic Model of Huang et al for Extranodal Natural Killer/T-Cell Lymphoma (ENKL)
- Prognostic Model of Tanaka et al for HIV-Related Diffuse Large B-Cell Lymphoma (DLBCL) in Brazil
- Signet Ring Cell Lymphoma
- Malignant Lymphoproliferative Disorders Associated with Acquired Immunodeficiency Syndrome (AIDS)
- Plasmablastic Lymphoma in an HIV-Positive Patient
- Immunostaining Algorithm of Hans et al for Subdividing Patients with Diffuse Large B-Cell Lymphoma (DLBCL) into Molecular Subtypes
- Immunostaining Algorithm of Choi et al for Subdividing Patients with Diffuse Large B-Cell Lymphoma (DLBCL) into Molecular Subtypes
- Clinical and Histologic Features of Louissaint et al for Distinguishing Atypical Epstein-Barr Virus (EBV) Lymphoproliferation (Pseudo-Lymphoma) from Malignant Lymphoma
- Double or Triple Hit Diffuse Large B-Cell Lymphoma (DLBCL)
- Lymph Node Infarction in Malignant Lymphoma
- Prognostic Score of the International Prognostic Factors Project for Patients with Advanced Hodgkin's Disease
- A Numerical Prognostic Index to Identify Poor Risk Patients with Hodgkin's Disease at Diagnosis
- Predictive Equation for Prognosis in Hodgkin's Disease of Gobbi et al
- Additional Analysis of Prognosis in Hodgkin's Disease Using the Predictive Equation of Gobbi et al
- Estimate for Expected Survival at Diagnosis in Hodgkin's Disease of Gobbi et al
- Criteria of the European Organization for Research and Treatment of Cancer Groupe d'Eude des Lymphomes de l'Adulte (EORTC-GELA) for Favorable Prognostic Groups of Hodgkin's Disease
- Prognostic Factors of Straus et al for Patients with Advanced Hodgkin's Disease
- Prognostic Factors of Wagstaff et al for Patients with Stage IIIB and IV Hodgkin's Disease
- Manchester Index of Lee et al for Identifying Risk of Progression in Patients with Hodgkins Disease
- Integrated Index of Gobbi et al for Patients with Advanced Hodgkin's Disease
- Prognostic Index of Smith et al for Children with Hodgkin's Disease Receiving Combined Modality Therapy
- Histologic Grades of MacLennan et al for Nodular Sclerosing Hodgkin's Disease
- Prognostic Score of Josting et al for Patients with Relapsed Hodgkin's Lymphoma
- Prognostic Score of Sup et al for Patients with Classical Hodgkin's Lymphoma
- Prognostic Factors of Wirth et al for a Patient with Lymphocyte Predominant Hodgkin's Disease Treated with Radiation Therapy Alone
- Grading Scheme of von Wasielewski et al for Nodular Sclerosing Hodgkin Disease
- Clinical Prediction Rule of Vassilakopoulos et al for Predicting Bone Marrow Involvement in a Patient with Hodgkin's Disease
- Prognostic Model of Low et al for a Patient with Hodgkin's Disease
- Prognostic Scoring System of Maurcort-Boulch et al for a Patient with Hodgkin's Disease
- Plasma Cytokine Signature Score of Casasnovas et al for Predicting Outcome in a Patient with Classic Hodgkin's Disease
- Transformation of Nodular Lymphocyte-Predominant Hodgkin's Lymphoma to Diffuse Large B-Cell or Other Form of Aggressive Lymphoma
- Lahey's Definition of Organ Dysfunction in Histiocytosis X
- The Southwest Oncology Group Staging System for Histiocytosis X
- Histiocytosis Grouping System of Osband et al.
- Factors Predictive of Progressive Disease in Patients with Langerhans Cell Histiocytosis
- Criteria for the Diagnosis of Primary Thrombocythemia
- Diagnostic Scoring System for Primary Thrombocythemia of Dudley et al
- Approach of Schafer for Management of Primary (Clonal) Thrombocythemia
- Treatment Algorithm of Tefferi and Barbui for a Patient with Essential Trombocythemia
- Risk Classification of Tefferi and Barbui for a Patient with Essential Thrombocythemia
- Risk Factors of Wolanskyj et al for Thrombotic Complications in a Patient with Essential Thrombocythemia
- Risk Factors of Wolanskyj et al for Mortality in a Patient with Essential Thrombocythemia
- Criteria of Campbell and Green for Primary Thrombocythemia Based on JAK2 Status
- Recommendations of an Ad Hoc International Expert Panel to Revise the WHO Criteria for Essential Thrombocythemia
- The 2001 WHO Criteria for Essential Thrombocythemia
- Risk Factors of Carobbio et al for Thrombosis in a Patient with Essential Thrombocythemia
- Acute Myocardial Infarction (AMI) in a Patient with Essential Thrombocythemia
- Response Criteria of the European LeukemiaNet Following Treatment of Essential Thrombocythemia
- Criteria of the European LeukemiaNet for Hydroxyurea Resistance or Intolerance in a Patient with Essential Thrombocythemia
- Polycythemia Vera Study Group Criteria for Diagnosis
- Criteria of Hoffman and Boswell for Polycythemia Vera
- Flow Chart of Barbui and Finazzi for Therapy Selection in Polycythemia Vera
- Treatment Algorithm of Tefferi for a Patient with Polycythemia Vera
- Risk Classification of Tefferi and Barbui for a Patient with Polycythemia Vera
- Criteria of Tefferi and Barbui for the Diagnosis of Polycythemia Vera
- Criteria of Campbell and Green for Polycythemia Based on JAK2 Status
- Recommendations of an Ad Hoc International Expert Panel to Revise the WHO Criteria for Polycythemia Vera
- The 2001 WHO Criteria for Polycythemia Vera
- Response Criteria of the European LeukemiaNet Following Treatment of Polycythemia Vera
- Criteria of the European LeukemiaNet for Hydroxyurea Resistance or Intolerance in a Patient with Polycythemia Vera
- Synthesis Prognostic Staging System of Kantarjian et al for CML
- Prognostic Score 1 of Hehlmann et al in CML
- Regression Models of Kantarjian et al for Predicting Survival in CML
- Relative Risk Equation of Sokal et al for Patients with Chronic Myelogenous Leukemia (CML)
- Relative Hazard Equation of Cervantes and Rozman for Patients with Chronic Myelogenous Leukemia (CML)
- Prognostic Score of Hasford et al for Patients with Chronic Myeloid Leukemia Treated with Interferon Alfa
- Negative Prognostic Factors of the Italian Cooperative Study Group for Staging Chronic Myeloid Leukemia
- Morphometric Bone Marrow Risk Classification Method of Kvasnicka et al for Patients with Chronic Phase Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (CML)
- Features of Atypical Chronic Myeloid Leukemia (aCML) in the WHO Classification of Mixed Myelodysplastic and Myeloproliferative Disorders
- Prognostic Score of Onida et al for Philadelphia Chromosome Negative, bcr/abl Negative Chronic Myelogenous Leukemia (CML)
- Criteria of the WHO Classification for the Accelerated and Blastic Phases of Chronic Myelogenous Leukemia (CML)
- Criteria for Therapeutic Response in Patients with Chronic Myelogenous Leukemia (CML) in the Chronic or Accelerated Phase
- The European Group for Bone Marrow Transplant (EBMT) Risk Score for a Patient with Chronic Myeloid Leukemia Following Marrow or Stem Cell Transplant
- The Risk Score of Passweg et al for the First Chronic Phase of CML (CML-CP Score)
- Model of Kantarjian et al for Predicting a Complete Cytogenetic Response to Imatinib Mesylate in a Patient with Philadelphia Chromosome Positive Chronic Phase CML
- Morphological Score of Lugli et al for Monitoring the Response of a Patient with Chronic Myelogenous Leukemia (CML) to Imatinib Mesylate
- Sudden Blast Crisis in a Patient with Philadelphia-Positive Chronic Myelogenous Leukemia (CML)
- Chronic Neutrophilic Leukemia (CNL)
- Score of Milojkovic et al Predicting Response of a Patient with Chronic Myelogenous Leukemia (CML) to a Second Generation Tyrosine Kinase Inhibitor
- Prognostic Groups of Visani et al in Myelofibrosis with Myeloid Metaplasia
- Prognostic Score of Hasselbalch and Jensen in Idiopathic Myelofibrosis
- Criteria for the Diagnosis of Myelofibrosis with Myeloid Metaplasia
- Prognostic Classes of Njoku et al in Myelofibrosis with Myeloid Metaplasia
- Factors of Cervantes et al for the Identification of Low and High Risk Prognostic Groups in Idiopathic Myelofibrosis
- Prognostic Classification of Barosi et al for Myelofibrosis with Myeloid Metaplasia
- Prognostic Factors of Kvasnicka et al for Idiopathic Osteomyelofibrosis
- The Lille Scoring System of Dupriez et al for Predicting Survival in Agnogenic Myeloid Metaplasia
- Severity Score of Barosi et al for Myelofibrosis with Myeloid Metaplasia (Myelodepletive and Myeloproliferative Indices)
- Risk Classification of Tefferi and Barbui for Myelofibrosis with Myeloid Metaplasia
- CBC-Based Scoring System of Dingli et al for a Patient with Agnogenic Myeloid Metaplasia
- Guidelines of Tefferi and Deeg for Therapy in a Patient with Myelofibrosis and Myeloid Metaplasia
- Criteria of Campbell and Green for Myelofibrosis Based on JAK2 Status
- Score of Elliott et al for Survival in Primary Myelofibrosis (New Mayo Score)
- Recommendations of an Ad Hoc International Expert Panel to Revise the WHO Criteria for Primary Myelofibrosis
- WHO Criteria (2001) for the Prefibrotic Stage of Primary Myelofibrosis (PMF)
- WHO Criteria (2001) for the Fibrotic Stage of Primary Myelofibrosis (PMF)
- Risk Factors of Huang et al for Leukemia Transformation in a Patient with Primary Myelofibrosis
- Prognostic Factors of Cervantes et al in a Young Patient with Myelofibrosis and Myeloid Metaplasia
- Circulating CD34+ Cells in a Patient with Myelofibrosis with Myeloid Metaplasia
- Predictive Factors of Kreft et al for Marrow Fibrosis in a Patient with Pre-Fibrotic Chronic Idiopathic Myelofibrosis
- Grading Scheme of Okamura et al for Primary Chronic Myelofibrosis
- Prognostic Score of Cervantes et al for Primary Myelofibrosis Based on the IWGMRT
- Criteria of Tam et al for an Accelerated Phase (AP) in Myelofibrosis
- Dynamic International Prognostic Scoring System (DIPSS) of Passamonti et al for Predicting Survival in Primary Myelofibrosis
- DIPSS Plus of Gangat et al for Evaluating a Patient with Primary Myelofibrosis
- Cytogenetic Risk Categories of Caramazza et al for a Patient with Primary Myelofibrosis
- Prognostic Factors of Barbui et al for a Patient with Essential Thrombocythemia versus Early Primary Myelofibrosis
- Clinical and Laboratory Findings of Barbui et al Associated with Progression of Myelofibrosis
- Criteria of the International Working Group for Progressive Disease Following Therapy of Myelofibrosis with Myeloid Metaplasia
- Sclerosing Extramedullary Hematopoietic Tumor (SEMHT)
- Prognostic Model of Gianelli et al for a Patient with Primary Myelofibrosis
- Scoring System of Morel et al for Waldenstrom's Macroglobulinemia
- Prognostic Score of Gobbi et al for Waldenstrom's Macroglobulinemia
- Prognostic Factors of Facon et al for Waldenstrom's Macroglobulinemia
- Prognostic Factors and Diagnostic Criteria of Owen et al for Waldenstrom's Macroglobulinemia
- Prognostic Score of Baldini et al for Predicting Evolution of Asymptomatic Macroglobulinemia (IgM MGUS or Indolent Waldenstrom's Macroglobulinemia)
- Prognostic Models of Ghobrial et al for a Newly Diagnosed Patient with Symptomatic Waldenstrom's Macroglobulinemia
- International Prognostic Scoring System (IPSS) for Waldenstrom's Macroglobulinemia
- Risk Factors of Kyriakou et al Affecting Overall Survival for a Patient Waldenstrom’s Macroglobulinemia Following Autologous Stem Cell Transplantation
- Viscosity in Patients with Leukemia
- Hyperviscosity Syndrome in Patients with Leukemia
- Leukostasis in Patients with Leukemia
- Pseudohypoxemia in Patients with Hyperleukocytosis
- Grades of Novotny et al for Symptoms in Hyperleukocytic Leukemia
- Tumor Burden Index in Cutaneous T-Cell Lymphoma
- TNM Staging of Cutaneous T-Cell Lymphoma
- Histopathologic Criteria of Cox for Mycosis Fungoides
- The Severity-Weighted Assessment Tool (SWAT) for Mycosis Fungoides
- Prognostic Features of Gniadecki et al for CD56-Positive Extranodal Lymphoma with Cutaneous Involvement
- Cutaneous B-Cell Lymphoma Prognostic Index of Smith et al
- Pseudo-Sezary Syndrome in a Patient with AIDS
- Clinical and Laboratory Features of Sezary Syndrome
- Grading Lymph Node Involvement in Mycosis Fungoides or Sezary Syndrome
- Clinical Features of Primary Cutaneous Diffuse Large B-Cell Lymphoma of the Leg Type
- Clinical and Laboratory Features of Subcutaneous Panniculitis-Like T-Cell Lymphoma (SPTCL) with alpha-beta T-Cell Receptors
- Clinical and Laboratory Features of Cutaneous gamma-delta T-Cell Lymphoma (Subcutaneous Panniculitis-Like T-Cell Lymphoma with gamma-delta T-Cell Receptors)
- Risk Factors of Diamandidou et al for Large Cell Transformation in a Patient with Sezary Syndrome or Mycosis Fungoides
- Prognostic Factors of Diamandidou et al for a Patient with Sezary Syndrome or Mycosis Fungoides Undergoing Large Cell Transformation
- Clinical Features of Aggressive Primary Cutaneous T-Cell Lymphoma Localized to the Lower Leg
- Prognostic Factors of Woo et al for a Patient with Primary Cutaneous Anaplastic Large Cell Lymphoma
- Response Criteria of Olsen et al of Mycosis Fungoides and Sezary Syndrome to Therapy: Visceral Involvement
- Criteria of Amano et al for HTLV-1 Associated Cutaneous Adult T-Cell Leukemia/Lymphoma (ATLL)
- Prognostic Factors of Benner et al for a Patient with Transformed Mycosis Fungoides
- Algorithm of Song et al for Early Mycosis Fungoides (MF, Modified Score of Pimpinelli et al)
- Conditions Associated with Cutaneous Pseudolymphoma
- Acute Tumor Lysis Syndrome in Malignant Lymphoma or Lymphocytic Leukemias
- Penn Predictive Score of Tumor Lysis Syndrome (PPS-TLS) in Acute Myelogenous Leukemia
- Grading Classification of Cairo and Bishop for the Tumor Lysis Syndrome
- Predictive Factors of Truong et al for Tumor Lysis Syndrome in a Pediatric Patient with Acute Lymphoblastic Leukemia (ALL)
- Risk Factors of Coiffier et al for Tumor Lysis Syndrome
- Risk Stratification of a Patient with the Tumor Lysis Syndrome
- Dosing Rasburicase in a Patient at Risk for the Tumor Lysis Syndrome
- Treatment of Electrolyte Abnormalities in a Patient with the Tumor Lysis Syndrome
- Dosing Allopurinol in a Patient at Risk for the Tumor Lysis Syndrome
- Predictive Model of Montesinos et al for the Tumor Lysis Syndrome in a Patient with Acute Myeloid Leukemia
- Evaluation of Acute Leukemia with Positive Peroxidase or Sudan Black B Stains
- Evaluation of Acute Leukemia Negative for Peroxidase, Sudan Black B and Esterase Stains
- Subclassification of Acute Lymphoblastic Leukemia Using Immunocytochemical Stains
- The European Group for the Immunological Classification of Leukemias Scoring System for Identification of Biphenotypic Acute Leukemia (BAL)
- Scoring System of Thalhammer-Scherrer et al in Adult Acute Leukemia
- Scoring System of Moreau et al for Distinguishing CLL from Other B-Cell Lymphoproliferative Disorders
- Prognostic Factors of Archimbaud et al in Angioimmunoblastic Lymphadenopathy
- Angioimmunoblastic T-Cell Lymphoma (AITL) Prognostic Index of Tokunaga et al.
- Symptoms Associated with Plasma Hyperviscosity
- Indications for Plasmapheresis in Patients with Plasma Hyperviscosity
- Diagnostic Criteria for Hemophagocytic Lymphohistiocytosis
- Prognostic Factors for Adults with the Hemophagocytic Syndrome
- 2004 Update to the Diagnostic Criteria for Hemophagocytic Lymphohistiocytosis (HLH)
- Criteria of Ravelli et al for the Macrophage Activation Syndrome (MAS) in a Patient with Systemic Juvenile Idiopathic Arthritis
- Clinical and Pathologic Features of Hodgkin Lymphoma-Associated Hemophagocytic Syndrome
- EBV-Related Hemophagocytic Lymphohistiocytosis (HLH)
- Classification of McDaniel et al for Lymphoproliferative Disorders of Granular Lymphocytes (LDGL)
- Algorithm of Lamy and Loughram for Evaluation of Large Granular Lymphocytosis in the Blood
- Transient Myeloproliferative Disorder in Newborns with Trisomy 21 (Down Syndrome)
- Complications Associated with Transient Myeloproliferative Disorder (Transient Abnormal Myelopoiesis) in a Neonate with Trisomy 21
- Grading Scheme of Lipford et al for Lymphomatoid Granulomatosis
- Classification Scale of Wotherspoon et al for Gastric MALT Lymphoma
- TNM Staging of Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma
- Risk Factors of Curtis et al for Posttransplantation Lymphoproliferative Disorders in Patients After Bone Marrow Transplantation
- Criteria of Preiksaitis and Keay for Clonality and Epstein-Barr Virus (EBV) Status in Posttransplant Lymphoproliferative Disorder
- Risk Factors of Preiksaitis and Keay for Posttransplant Lymphoproliferative Disorder
- Prognostic Score of Ghobrial et al for an Adult with a Solid Organ Transplant and Post-Transplantation Lymphoproliferative Disorder
- Prognostic Factors of Evens et al for a Patient with Post-Transplantation Lymphoproliferative Disease (PTLD)
- Risk Factors for Posttransplant Lymphoproliferative Disorder (PTLD) in a Renal Transplant Patient Treated with Belatacept (Nulojix)
- Prognostic Score of Caillard et al for Post-Transplant Lymphoproliferative Disorder (PTLD)
- Prognostic Factors for a Follicular Dendritic Cell Sarcoma/Tumor
- Clinical and Laboratory Features of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- Immunophenotype of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- Clinical Features of Alpha Heavy Chain Disease (Mediterranean Abdominal Lymphoma)
- Clinical Features of Gamma Heavy Chain Disease (Franklin's Disease)
- Clinical Features of Mu Heavy Chain Disease
- Extensive Sarcoid-Like Granulomas in a Patient with a Lymphoproliferative Disorder (Sarcoidosis-Lymphoma Syndrome)
- Malignancy-Sarcoidosis Syndrome
- Clinical and Laboratory Findings in a Patient with Multicentric Castleman's Syndrome
- Histologic Features of Multicentric Castleman's Syndrome
- Criteria of Gerard et al for an Attack of Multicentric Castleman's Disease (MCD)
- Oncogenetic Risk Classification of Trinquand et al for Adult T-Cell Acute Lymphoblastic Leukemia (T-ALL)
- Classification of CNS Status in a Patient with Acute Lymphoblastic Leukemia (ALL)
- Interpretation of a Bloody CSF Tap in a Patient Presenting with Acute Lymphoblastic Leukemia (ALL)
- Central Nervous System (CNS) Relapse in a Patient with Acute Lymphoblastic Leukemia (ALL)
- Prognostic Factors of Mauro et al for a Patient with Early Onset (Age <= 55 Years) Chronic Lymphocytic Leukemia (CLL)
- Multiple Myeloma: Interleukins
- Multiple Myeloma: RNA Index
- Multiple Myelomas: Serum LDH
- Multiple Myeloma: Tumor Ploidy
- Classification of Wu et al for Primary Effusion-Based Lymphoma (PEL)
- Loss of CD20 Expression in B-Cell Malignant Lymphomas Associated with Rituximab Therapy
- Prognostic Factors of Orwat and Batalis for a Patient with Intravascular Large B-Cell Lymphoma (IVLBCL)
- Prognostic Model of Perry et al for Diffuse Large B-Cell Lymphoma (DLBCL)
- Ratio of Absolute Neutrophil to Lymphocyte Counts in Classic Hodgkin's Disease
- International Prognostic Score for Essential Thrombocythemia (IPSET) of Passamonti et al
- European Treatment and Outcome Study for CML (EUTOS) Score for a Patient Treated with Imatinib
- Clinical and Laboratory Findings Associated with Large Granular Lymphocytic Leukemia
- Non-Hodgkin’s Lymphoma in Patients Infected with Hepatitis C Virus (HCV)
- Prognostic Index in Cytogenetically Normal Acute Myeloid Leukemia (PINA) of Pastore et al for Overall Survival (OS)
- Prognostic Index in Cytogenetically Normal Acute Myeloid Leukemia (PINA) of Pastore et al for Relapse-Free Survival (RFS)
- Risk Score of Sanz et al for Acute Promyelocytic Lekemia from the PETHEMA and GIMEMA Cooperative Groups
- CBC Score of Park et al for Prognosis in Acute Promyelocytic Leukemia (APL)
- Immunophenotypic Markers of Poor Prognosis in Acute Promyelocytic Leukemia (APML)
- Prognostic Score of Moreau et al for Predicting Early Progression in a Patient with Multiple Myeloma
- Aspiration Cytology of the Lower Abdominal Fat Pad in the Diagnosis of Systemic Amyloidosis
- Mediastinal Gray Zone Lymphoma (Large B-Cell Lymphoma with Hodgkin Features, Hodgkin-Like Anaplastic Large Cell Lymphoma)
- National Comprehensive Cancer Network International Prognostic Index (NCCN-IPI) for a Patient with Diffuse Large B-Cell Lymphoma
- Histologic Staging System of Liu et al for Breast Implant-Associated Anaplastic Large Cell Lymphoma (BI-ALCL)
- MUM-1 and Ki-67 Expression in Follicular Lymphoma
- Anaplastic Large Cell Lymphoma Associated with Breast Implant
- Composite Lymphoma
- Pyothorax-Associated Lymphoma (PAL)
- Prognostic Significance of PET (Positron Emission Tomography) Scan Findings After 1 and 2 Cycles of Chemotherapy for Hodgkin's Disease
- Nasopharyngeal Hodgkin's Disease
- Granulomatous Slack Skin Syndrome (GSS)
- Differential Diagnosis of Hemophagocytic Lymphohistiocytosis (HLH)
- Prognostic Score of Nowakowski et al for a Patient with T-Cell Large Granular Lymphocytic Leukemia (LGLL)
- Model of Hill et al for Predicting Risk of Progression to Myeloma in a Patient with Solitary Plasmacytoma of Bone
- Revised International Staging System (R-ISS) of Palumbo et al for Myeloma
- Familial Myeloma
- Criteria of Fernandez de Larrea et al for Progression of Plasma Cell Leukemia (PCL, IMWG Criteria)
- Criteria of Fernandez de Larrea et al for Relapse of Plasma Cell Leukemia (PCL) After Complete Remission (IMWG Criteria)
- Criteria of Fernandez de Larrea et al for Remission of Plasma Cell Leukemia (PCL, IMWG Criteria)
- Criteria of Palladini et al for Response to Therapy by a Patient with Immunoglobulin Light Chain Amyloidosis
- Enteropathy-Associated T-Cell Lymphoma (EATL) Prognostic Index (EPI) of de Baaij et al
- Types of Enteropathy-Associated T-Cell Lymphoma (EATL)
- Hodgkin-Like Cells (cHL) in Non-Hodgkin's Lymphoma
- Autoimmune Conditions in Patients with Marginal Zone Lymphoma (MZL)
- Risk Factors of Jabbour et al for Outcome in a Patient with Ph+ Chronic Myeloid Leukemia (CML) in Chronic Phase Treated with Nilotinib After Imatinib
- Prognostic Model of Scarisbrick et al for Patients with Advanced Stage Mycosis Fungoides or Sezary Syndrome
- Hydroa Vacciniforme-Like Lymphoma (HVLL)
- Indications of Lamy and Loughran to Treat a Patient with Large Granular Lymphocytic Leukemia (LGLL)
- Classification for Acute Leukemias of Ambiguous Lineage
- Comprehensive Prognostic Index of Pflug et al for a Patient with Chronic Lymphocytic Leukemia (CLL, Model of the German CLL Study Group, GCLLSG)
- International Prognostic Index for a Patient with Chronic Lymphocytic Leuekemia (CLL-IPI)
- European ALMA Score for a Patient with Acute Myeloid Leukemia (AML) Who Is Treated with Azacitidine
- Acute Myeloid Leukemia (AML) Maturity Score of Schneider et al Based on Flow Cytometry
- Integrative Prognostic Risk Score (IPRS) of Damm et al for Acute Myeloid Leukemia (AML) with Normal Karyotype
- Risk-Adapted Model of Yoon et al for an Older Adult with Acute Myeloid Leukemia (AML)
- Model of Mauer et al for Predicting Event-Free Survival at 24 Months for a Patient with Diffuse Large B-cell Lymphoma (DLBCL)
- MIPI-c of Hoster et al for Mantle Cell Lymphoma
- Predictive Factors of Sarkozy et al for Histologic Transformation in a Patient with Follicular Lymphoma
- CNS International Prognostic Index (CNS IPI) of Schmitz et al for a Patient with Diffuse Large B-Cell Lymphoma (DSHNHL Prognostic Model)
- Risk Model of Guglielmi et al for a Patient with Diffuse Large Cell Lymphoma at First Relapse
- Risk Factors of Olszewski et al for 30-Day Mortality in an Older Adult with Diffuse Large B-Cell Lymphoma (DLBCL) After Rituximab-Based Immunochemotherapy
- Prognostic Score of Barta et al for AIDS-Related Lymphoma: HIV Subscore
- Prognostic Score of Barta et al for AIDS-Related Lymphoma: Total ARL-IPI
- Extranodal Scoring System of Hwang et al for Evaluating a Patient with Diffuse Large B-Cell Lymphoma (DLBCL)
- Use of Platelet Count and Serum Albumin to Predict Prognosis for an Elderly Adult with Diffuse Large B-Cell Lymphoma (DLBCL, Platelet-Albumin Score of Ochi et al)
- 3-Item International Prognostic Score (IPS-3) of Diefenbach et al for a Patient with Hodgkin’s Disease
- Features of Appel et al for Low-Risk Pediatric Lymphocyte-Predominant Hodgkin's Lymphoma (LPHL) That Requires Minimal Therapy
- Histological Score of Shet et al for Nodular Lymphocyte Predominant Hodgkin Disease
- Criteria of Campiotti et al for Blast Crisis in a Patient with Chronic Myeloid Leukemia (CML)
- Cells of Origin for a Blast Crisis in a Patient with Chronic Myeloid Leukemia (CML)
- Clinical Features of the Bing-Neel Syndrome in a Patient with Waldenstrom's Macroglobulinemia
- Criteria for the Diagnosis of the Bing-Neel Syndrome in a Patient with Waldenstrom's Macroglobulinemia
- Prognostic Factors of Castillo et al for Bing-Neel Syndrome (BNS) in a Patient with Waldenstrom's Macroglobulinemia
- Cutaneous Lymphoma International Prognostic Index (CLIPi) of Benton et al for Mycosis Fungoides and Sezary Syndrome: Model for Early Stage Disease
- Cutaneous Lymphoma International Prognostic Index (CLIPi) of Benton et al for Mycosis Fungoides and Sezary Syndrome: Model for Late Stage Disease
- HScore of Fardet et al for the Diagnosis of the Reactive Hemophagocytic Syndrome
- TAFRO Syndrome (Castleman-Kojima Syndrome)
- Prognostic Model of Rollig et al for a Patient with Acute Myeloid Leukemia (AML) with Intermediate-Risk Karyotype
- Indications of Grever et al for Therapy of a Patient with Hairy Cell Leukemia (HCL)
- Risk Factors of Tam et al for a Patient with Chronic Lymphocytic Leukemia (CLL) with De Novo Deletion of 17p13.1
- Simplified Risk Scores of Stephens et al for a Patient with Chronic Lymphocytic Leukemia (CLL) with del(17p13.1): Treatment-Free Survival
- Simplified Risk Scores of Stephens et al for a Patient with Chronic Lymphocytic Leukemia (CLL) with del(17p13.1): Overall Survival
- Primary Adrenal Lymphoma (PAL)
- Models of Fragkioudaki et al for Risk of Non-Hodgkin's Lymphoma in a Patient with Sjogren's Syndrome
- Second-Line Age-Adjusted International Prognostic Index (sAAIPI)
- Polycythemia Vera Risk Score of Tefferi et al
- Risk Factors of Polverelli et al for Infection in a Patient with Myelofibrosis
- Clinical Findings of Clarke et al Seen in Pediatric Leukemia
- Prognostic Model of Delgado et al for Chronic Lymphocytic Leukemia (CLL)
- Day of Blast Disappearance (DOBD) and Other Prognostic Factors of Short et al for Acute Myeloid Leukemia (AML)
- Prognostic Groups of the European LeukemiaNet Based on Cytogenetics and Molecular Genetics for Acute Myeloid Leukemia (AML)
- Blastic/Blastoid Transformation of Follicular Lymphoma
- Clinical Prediction Rule of Baldini et al for Malignant Lymphoma in a Patient with Primary Sjogren's Syndrome
- Factors of Solans-Laque et al for Malignant Lymphoma in a Patient with Primary Sjogren's Syndrome
- Risk Factors of Baimpa et al for Malignant Lymphoma in a Patient with Primary Sjogren Syndrome
- Prognostic Factors of Ioannidis et al for Lymphoproliferative Disorders and Mortality in a Patient with Primary Sjogren's Syndrome
- Predictors of Theander et al for Malignant Lymphoma in a Patient with Primary Sjogren's Syndrome
- Clinical Findings of Voulgarelis et al Associated with Malignant Lymphoma in a Patient with Primary Sjogren's Syndrome
- Spontaneous Regression of a Malignant Hodgkin's or Non-Hodgkin's Lymphoma
- Favorable Categories of Sasse et al for Early Hodgkin Disease
- International Working Group for Myeloproliferative Research and Treatment (IWG-MRT) Criteria for Post-Essential Thrombocythemia Myelofibrosis
- Prognostic Factors of Mudireddy et al for a Patient with Essential Thrombocythemia
- Triple-Negative Myeloproliferative Neoplasm (MPN)
- International Working Group for Myeloproliferative Research and Treatment (IWG-MRT) Criteria for Post-Polycythemia Vera Myelofibrosis
- Criteria of Grever for Progression in Hairy Cell Leukemia (HCL) After Therapy
- Hairy Cell Leukemia Variants (Atypical Hairy Cell Leukemia)
- Indolent Prognostic Index (iATL-PI) of Katsuya et al for Chronic or Smoldering Adult T-Cell Leukemia/Lymphoma (ATL)
- Predictors of Fink et al for a Poor Outcome of a Patient with Chronic Lymphocytic Leukemia (CLL) Following Chemoimmunotherapy
- Progression-Risk Score of Gentile et al for Predicting Treatment-Free Survival for a Patient with Early Stage Chronic Lymphocytic Leukemia (CLL)
- Risk Factors of Morabito et al for Progression in a Patient with Binet Stage A Chronic Lymphocytic Leukemia (CLL)
- Prognostic Model of Morabito et al for Chronic Lymphocytic Leukemia (CLL) Including the Total Serum Light Chain Concentration
- Laboratory Score of Cohen et al for Predicting Early Treatment of a Patient with Early Stage Chronic Lymphocytic Leukemia (CLL)
- Prognostic Score of Condoluci et al for a Patient with Early Stage Chronic Lymphocytic Leukemia (CLL)
- Predictors of Terebelo et al for Early Mortality for a Patient with Multiple Myeloma
- Risk Factors of Hsu et al for Early Mortality in a Patient with Recently Diagnosed Multiple Myeloma
- Criteria of Usmani et al for Ultra High Risk Multiple Myeloma
- CRAB Findings in Multiple Myeloma
- Risk Assessment Model of Avet-Loiseau et al for a Patient with Myeloma That Combines ISS Stage and FISH
- Revised Criteria of the International Myeloma Working Group (IMWG): Smoldering Multiple Myeloma (SMM)
- Criteria for High Risk Smoldering Multiple Myeloma (SMM)
- Criteria of the International Myeloma Working Group for IgM MGUS (IgM Monoclonal Gammopathy of Undetermined Significance)
- Criteria of the International Myeloma Working Group for Non-IgM MGUS (Non-IgM Monoclonal Gammopathy of Undetermined Significance, IgA or IgG Monoclonal Gammopathy of Undetermined Significance)
- Criteria of the International Myeloma Working Group for Light Chain MGUS (Monoclonal Gammopathy of Undetermined Significance)
- Criteria of the International Myeloma Working Group for Solitary Plasmacytoma
- Criteria of the International Myeloma Working Group for Multiple Myeloma
- Immunoparesis in Myeloma
- Oral Manifestations of Multiple Myeloma
- Criteria of Grogan et al for Organ Involvement in a Patient with Biopsy-Proven Amyloidosis
- Primary Intraocular Malignant Lymphoma (PIOL)
- 5-Point Score (5PS) Score for PET Scan in a Patient with Malignant Lymphoma (Deauville Scale)
- Revised Ann Arbor Staging System for Primary Malignant Lymphoma from the Lugano Conference
- Criteria for Lymph Node Involvement from the Lugano Conference on Malignant Lymphoma
- Criteria for Splenic Involvement from the Lugano Conference on Malignant Lymphoma
- Criteria for Hepatic Involvement from the Lugano Conference on Malignant Lymphoma
- Criteria for Central Nervous System (CNS) Involvement from the Lugano Conference on Malignant Lymphoma
- Criteria for Involvement of "Other" Body Sites from the Lugano Conference on Malignant Lymphoma
- Criteria for Complete Therapeutic Response (CR) of a Malignant Lymphoma from the Lugano Conference
- Criteria for Partial Therapeutic Response (PR) of a Malignant Lymphoma from the Lugano Conference
- Criteria for No Therapeutic Response (Stable Disease) of a Malignant Lymphoma from the Lugano Conference
- Criteria for Progression of a Malignant Lymphoma After Therapy from the Lugano Conference
- Scoring System of Bachy et al for Evaluating a Patient with Follicular Lymphoma Who Is Treated Initially with Immunochemotherapy (PRIMA-PI)
- Prognostic Score of Kong et al for a Patient with Diffuse Large B-Cell Lymphoma (DLBCL)
- Prognostic Factors of Wang et al for Gastric Lymphoma
- Clinical Score of Choi et al for Langerhans Cell Histiocytosis (LCH)
- Response Categories in Langerhans Cell Histiocytosis (LCH)
- Mutation-Enhanced International Prognostic Score System (MIPSS70) of Guglielmelli et al for a Patient with Primary Myelofibrosis
- Mutation-Enhanced International Prognostic Score System with Cytogenetic Data (MIPSS70-plus) of Guglielmelli et al for a Patient with Primary Myelofibrosis
- MIPSS70+ Version 2.0 for Evaluating a Patient with Primary Myelofibrosis
- Revised Cytogenetic Risk Stratification of Tefferi et al for Primary Myelofibrosis
- Clinical and Laboratory Features of Primary Cutaneous Acral CD8+ T-Cell Lymphoma
- Clinical and Laboratory Features of Primary Cutaneous Aggressive Epidermotropic CD8+ Cytotoxic T-Cell Lymphoma
- MALT Lymphoma International Prognostic Index (MALT-IPI) of Thieblemont et al
- Integrated Mutational and Cytogenetic Model of Rossi et al in Chronic Lymphocytic Leukemia (CLL)
- Predictors of Rosinol et al for Malignant Transformation in a Patient with Monoclonal Gammopathy of Undetermined Significance (MGUS)
- Criteria of Yabe et al for Hepatosplenic T-Cell Lymphoma (HSTCL)
- Prognostic Factors of Yabe et al for Hepatosplenic T-Cell Lymphoma (HSTCL)
- Kyota Prognostic Index (KPI) of Kobayashi et al for Diffuse Large B-Cell Lymphoma (DLBCL)
- Prognostic Score of Montalban et al for a Patient with Splenic Marginal Zone Lymphoma
- Prognostic Model of Chen et al for Diffuse Large B-Cell Lymphoma (DLBCL)
- ACA (Age, Comorbidity, Albumin) Index of Miura et al for a Patient with Diffuse Large B-Cell Lymphoma
- Prognostic Index of Kang et al for a Patient with Diffuse Large B-Cell Lymphoma (DBLCL)
- SIL Index of Tomita et al for a Patient with Diffuse Large B-Cell Lymphoma (DLBCL)
- Prognostic Score of Candelaria et al for an Older Adult with Diffuse Large B-Cell Lymphoma (DLBCL)
- Inflammation-Based Cumulative Prognostic Score (ICPS) of Sun et al for a Patient with Diffuse Large B-Cell Lymphoma (DLBCL)
- Revised International Prognostic Index (R-IPI) for a Patient with Diffuse Large B-Cell Lymphoma
- Elderly International Prognostic Index (E-IPI) for a Patient with Diffuse Large B-Cell Lymphoma
- AMLPI Prognostic Index of Batty et al for a Patient with Diffuse Large B-Cell Lymphoma (DLBCL)
- Prognostic Model of Zhao et al for a Patient with Diffuse Large B-Cell Lymphoma (DLBCL)
- Prognostic Index of Matsumoto et al for a Patient with Diffuse Large B-Cell Lymphoma (DLBCL)
- Prognostic Model of Salles et al for a Patient with Diffuse Large B-Cell Lymphoma (DLBCL)
- ABE3 Score of Prochazka et al for a Patient with Diffuse Large B-Cell Lymphoma (DLBCL)
- GELTAMO International Prognostic Index (IPI) for a Patient with Diffuse Large B-Cell Lymphoma (DLBCL)
- Comorbidity NCCN-IPI (cNCCN-IPI) of Antic et al for Patients with Diffuse Large B-Cell Lymphoma (DLBCL)
- Prognostic Model of Kanemasa et al for a Patient with Diffuse Large B-Cell Lymphoma (DLBCL)
- Masked/Prodromal Polycythemia Rubra Vera (PRV)
- Genetically Inspired Prognostic Scoring System (GIPSS) of Tefferi et al for Patients with Primary Myelofibrosis
- Bone Marrow Fibrosis Associated with Visceral Leishmaniasis (Kala-Azar)
- Misdiagnosis of Early Mycosis Fungoides (MF)
- Criteria of Kelati et al for Mycosis Fungoides
- Criteria of Yabe et al for Large Granular T-Cell Leukemia (LGL)
- Prognostic Risk Score of Soumerai et al for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL, BALL Score)
- Modified NCCN-IPI Score of Melchardt et al for an Older Adult with Diffuse Large B-Cell Lymphoma (DLBCL)
- HPLL Prognostic Index of Montalban et al for Splenic Marginal Zone Lymphoma
- Prognostic Model of Zhu et al for a Patient with Mantle Cell Lymphoma
- Prognostic Model of Wilcox et al Using Absolute Monocyte and Lymphocyte Counts in a Patient with Diffuse Large B-Cell Lymphoma (DLBCL)
- ABE4 Score of Prochazka et al for a Patient with Diffuse Large B-Cell Lymphoma (DLBCL)
- Prognostic Model of Tefferi et al for Postsplenectomy Survival for a Patient with Myelofibrosis
- Algorithm of Pimpinelli et al for Early Mycosis Fungoides
- Prognostic Model of Hong et al for Angioimmunoblastic T-Cell Lymphoma
- Model of Molica et al for Chronic Lymphocytic Leukemia (CLL)
- Model of Zhang et al for Predicting Early Death for a Patient with Acute Promyelocytic Leukemia (APML)
- Diagnostic Criteria of Valent et al for Basophilic Leukemia
- Prognostic Indicators of Jurczyszyn et al for a Patient with Primary Plasma Cell Leukemia
- Prognostic Scoring System of Jung et al for a Patient with Myeloma
- Prognostic Factors of Kyle et al for Monoclonal Gammopathy of Undetermined Significance (MGUS)
- Risk Model of Turesson et al for Progression of Monoclonal Gammopathy of Undetermined Significance (MGUS)
- Criteria of Dispenzieri et al for Hematologic Therapeutic Response in a Patient with Light Chain Amyloidosis
- Prognostic Criteria of Sachchithanantham et al for Monoclonal IgM-Related Light Chain Amyloidosis
- qPET of an Interim FDG-PET Scan for a Patient with Malignant Lymphoma
- Prognostic Score of Barrans et a for Diffuse Large B-Cell Lymphoma (DLBCL)
- Prognostic Model of Kanemasa et al for CNS Relapse in a Patient with Diffuse Large B-Cell Lymphoma (DLBCL)
- Risk Factors of Hollender et al for Central Nervous System (CNS) Involvement in Non-Hodgkin's Lymphoma
- Prognostic Indices of Gang et al for a Patient with Diffuse Large B-Cell Lymphoma (DLBCL-PI)
- Nomogram of Maurer et al for Overall Survival for a Patient with Diffuse Large B-Cell Lymphoma (DLBCL) Following Frontline Immunochemotherapy
- International Pediatric Non-Hodgkin Lymphoma (IPNHL) Staging System
- Criteria of Engert et al for Early-Stage Hodgkin's Lymphoma
- Staging Classification of Carbone et al for Hodgkin's Disease
- Monocytosis in Primary Myelofibrosis
- ISCL/EORTC TNM Classification for Primary Cutaneous Lymphoma Other Than Mycosis Fungoides or Sezary Syndrome
- CLL Score of Matutes et al
- Prognostic Factors of Li et al for Chronic Lymphocytic Leukemia (CLL) in a Chinese Patient
- Survival Risk Score for Ibrutinib (SRSI) of Gentile et al for a Patient with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
- Prognostic Model of Ma et al for an Adult Patient with Acute Myeloid Leukemia (AML)
- Hematopoietic Score of Al Saleh et al for a Patient with Newly Diagnosed Multiple Myeloma
- Red Cell Distribution Width (RDW) and Prognosis for a Patient with Light Chain Amyloidosis
- Clinical Red Flags of Mendelson et al for Light Chain Amyloidosis in a Patient with Myeloma
- Amyloid Arthropathy
- Diagnostic Criteria of Matutes et al for Splenic Marginal Zone Lymphoma (SMZL)
- L-GPS Score of Jung et al for Diffuse Large B-Cell Lymphoma (DLBCL)
- Chinese Prognostic Index for Natural Killer Cell Lymphoma (C-PINK) of Hong et al
- Prognostic Indices of Kim et al for Natural Killer Cell Lymphoma (PINK, PINK-E)
- Prognostic Score of Liu et al for Newly Diagnosed Primary CNS Lymphoma (Taipei Score)
- EUTOS Long-Term Survival (ELTS) Score of Pfirrmann et al
- Infiltration of the Bone Marrow in Angioimmunoblastic T-Cell Lymphoma
- Modified MALT-IPI Score of Kim et al Incorporating Serum Beta-2-Microglobulin (MALT-IPI-B)
- Criteria of the All Japan TAFRO Syndrome Research Group for TAFRO Syndrome
- Disease Severity Classification of the All Japan TAFRO Syndrome Research Group for TAFRO Syndrome
- Prognostic Model of Ahn et al for a Patient with Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib (CLL4 Model)
- Molecular Criteria of Rossi et al for Predicting Response of a Patient with Chronic Lymphocytic Leukemia (CLL) to Chemotherapy
- Chronic Lymphocytic Leukemia (CLL) Associated Liver Dysfunction
- CLL1-PM Prognostic Model of Hoechstetter and the German CLL Study Group for Newly Diagnosed CLL Patients in Binet Stage A
- International Prognostic Score for Early Stage Chronic Lymphocytic Leukemia (IPS-E)
- Simplified CONUT Score of Senjo et al for an Elderly Patient with Acute Myeloid Leukemia (AML)
- Prognostic Index of Tachibana et al for a Patient with Relapsed or Refractory Acute Myeloid Leukemia (AML) Undergoing Hematopoietic Stem Cell Transplantation (HSCT)
- Myeloid Sarcoma (Granulocytic Sarcoma, Chloroma)
- Prognostic Model of Chavda et al for a Myeloma Patient Who Relapses After Upfront Autologous Stem Cell Transplantation
- Myeloma Spine and Bone Damage Score (MSBDS) of Tagliafico et al
- Chronic Conditions Associated with Secondary Amyloidosis
- Disease Severity Score of Damy et al for Hereditary Transthyretin Amyloidosis (ATTRv): Cardiac and Cardiovascular Involvement
- Disease Severity Score of Damy et al for Hereditary Transthyretin Amyloidosis (ATTRv): Noncardiac and Nonnneurologic Manifestations
- Disease Severity Score of Damy et al for Hereditary Transthyretin Amyloidosis (ATTRv): Sensory Findings
- Disease Severity Score of Damy et al for Hereditary Transthyretin Amyloidosis (ATTRv): Motor Function
- Disease Severity Score of Damy et al for Hereditary Transthyretin Amyloidosis (ATTRv): Total Score
- Amyloidosis and the Underlying Protein
- Prognostic Score of Bento et al for a Patient with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with R-CHOP
- Prognostic Model of Federico et al for Peripheral T-Cell Lymphoma Not Otherwise Specified (PTCL-NOS)
- Prognostic Index of Durot et al for Transformed Waldenstrom's Macroglobulinemia
- Histologic Transformation of (Transformed) Waldenstrom's Macroglobulinemia
- Revised International Prognostic Score for Waldenstrom's Macroglobulinemia. Leukemia (rIPSSWM)
- Predictive Model of Vallapureddy et al for Leukemic Transformation from Primary Myelofibrosis
- Prognostic Factors of Tefferi et al for Blast Phase Myeloproliferative Neoplasm (MPN-BP)
- Mayo Clinic Revised Criteria for the Diagnosis of Plasma Cell Leukemia (PCL)
- Follicular Lymphoma Evaluation Index (FLEX) of Mir et al
- Prognostic Model of Lee et al for an Older Adult with Diffuse Large B Cell Lymphoma (DLBCL)
- Nomogram of Han et al for Predicting Overall Survival for a Patient with Diffuse Large B-Cell Lymphoma (DLBCL)
- Nomogram of Lu et al for Overall Survival of Patient with Burkitt Lymphoma
- Prognostic Score of Fanale for Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL)
- Childhood Hodgkin International Prognostic Score (CHIPS) of Schwartz et al
- Prognostic Model of Huang et al for a Patient with Angioimmunoblastic T-Cell Lymphoma (AITL Risk Index, AITLI))
- Acute Lymphoblastic Leukemia (ALL) with MEF2D Rearrangement
- Alternative InternationalPrognostic Index-E (AIPS-E) for Binet A Chronic Lymphocytic Leukemia (CLL)
- Flow Cytometry Score of Kohnke et al for Chronic Lymphocytic Leukemia (CLL)
- Immune Risk Score of Wang et al for a Patient with Acute Myeloid Leukemia (AML) Receiving Chemotherapy
- Nomogram of Wang et al for Predicting Survival of a Patient with Acute Myeloid Leukemia (AML) Receiving Chemotherapy
- Early Relapse After Autologous Stem Cell Transplant and Prognosis for a Patient with Myeloma
- Risk Stratification Scores of Hajek et al for Relapsed Multiple Myeloma: Disease Aggressiveness Risk Score
- Risk Stratification Scores of Hajek et al for Relapsed Multiple Myeloma: Frailty Risk Score and Total Risk Score
- Elderly Prognostic Index (EPI) of Spina et al for an Older Adult with Diffuse Large B-Cell Lymphoma (DLBCL)
- TRAIL Score of Harris et al for Predicting Immunochemotherapy Tolerability for a Patient with Diffuse Large B-Cell Lymphoma (DLBCL)
- Burkitt Lymphoma International Prognostic Index (BL-IPI)
- Prognostic Nomogram of Shen et al for a CD5-Positive Diffuse Large B-Cell Lymphoma (DLBCL)
- HLAMA Score of Gao et al for Gastrointestinal Diffuse Large B-Cell Lymphoma (DLBCL)
- Immune Risk Score of Ma et al for Diffuse Large B-Cell Lymphoma (DLBCL)
- Nomogram of Fan et al for Predicting Survival in a Patient with Intestinal Diffuse Large B-Cell Lymphoma (DLBCL)
- Nomogram of Ma et al for Diffuse Large B-Cell Lymphoma (DLBCL)
- Secondary Intraocular Lymphoma (SIOL)
- Nomogram of Zhong et al for Evaluating a Patient with Aggressive Non-Hodgkin's Lymphoma
- Prognostic Nomogram of Cai et al for a Patient with Diffuse Large B-Cell Lymphoma (DLBCL) in the Rituximab Era
- Severe Iron Deficiency Anemia Masking Polycythemia Rubra Vera (PRV)
- Signs and Symptoms in Patients with Polycythemia Rubra Vera (PRV)
- Three-Factor Model (CLL3) of Molica et al for Chronic Lymphocytic Leukemia (CLL)
- Predictors of Lancman et al for Patients in the Blast Phase of Myeloproliferative Neoplasms
- Prediction Model of Osterroos et al for Predicting Early Mortality in Acute Promyelocytic Leukemia
- Score of Cai et al for Prediction of Early Death for a Patient with Acute Promyelocytic Leukemia (APML)
- Modified Sanz Model of Lou et al for a Patient with Newly Diagnosed Acute Promyelocytic Leukemia
- Triple-Class Refractory (TCR) Multiple Myeloma
- Double and Triple Hit Cytogenetics in Multiple Myeloma
- Myeloma Research Alliance Risk Profile (MRP) of Cook et al for Transplant-Ineligible Patients
- Orthopedic Changes in Amyloidosis
- Prognostic Factors of Gao et al for Primary CNS Lymphoma
- Beta2-Microglobulin to Lymphocyte Ratio Index (betaLRI)
- Prognostic Model of Dai et al for Extranodal NK/T-Cell Lymphoma (ENKTL)
- Hemoglobin-Platelet Index (HPI) of Taniguchi et al for a Patient with Diffuse Large B-Cell Lymphoma (DLBCL)
- Algorithm of Nabhan et al for Evaluating a Patient with Chronic Lymphocytic Leukemia (CLL)
- Criteria of Popov et al for a Pediatric Patient with ALL Who Can Be Cured with Low-Intensity Therapy
- Prognostic Score of Li et al for a Pediatric Patient with Acute Myeloid Leukemia (AML)
- Three Factor Model of Tefferi et al for a Patient with Acute Myeloid Leukemia (AML)
- Prognostic Model of Li et al for Pediatric Acute Myeloid Leukemia
- Predictors of McQuilten et al for Early Mortality for a Patient with Multiple Myeloma
- Prognostic Score of Yang et al for Newly Diagnosed Multiple Myeloma with 1q+
- Blastic Transformation of Mantle Cell Lymphoma (MCL)
- SALENTO Limited Stage Peripheral T-Cell Lymphoma (PTCL) Prognostic Model of Hapgood et al
- Nomogram of Wang et al for Predicting Survival of a Patient with Limited Stage Upper Aerodigestive Tract Extranodal Natural/T-Cell Lymphoma Nasal Type (ENKTCL)
- Prognostic Factors of Wang et al for a Patient wit Extranodal Natural Killer/T-cell Lymphoma (ENKTL) Nasal Type
- Use of Ki-67 Immunostaining to Distinguish Classic from Blastoid Mantle Cell Lymphoma (MCL)
- International T-Cell Index of Vose for a Patient with a Peripheral T-Cell Lymphoma (PTCL)
- Treatment Algorithm of Ramazanoglu et al for Spinal Lymphoma
- Nomogram of Liang et al for Predicting Overall Survival for a Patient with Hodgkin's Disease
- Model of Yhim et al for Risk Stratification of Relapsed or Refractory Hodgkin's Disease
- Score of Zhang et al for Predicting Failure-Free Survival for a Patient with Chronic Myeloid Leukemia (CML) Treated with Imatinib
- Mycosis Fungoides and Sezary Syndrome with Colonization by Staphylococcus aureus
- Mutations Associated with Primary Hemophagocytic Lymphohistiocytosis
- Screening Score of Li et al for Epstein-Barr Virus Related Hemophagocytic Lymphohistiocytosis (EBV-HLH)
- Prognostic Factors of Liu et al for a Patient with Acute Monocytic Leukemia (AML-M5)
- Frailty Score of Milani et al for a Patient with Newly Diagnosed Multiple Myeloma (Mayo Risk Score)
- Geriatric Assessment of Palumbo et al for an Elderly Patient with Multiple Myeloma (International Myeloma Working Group Frailty Score)
- Score of Tanaka et al for Intravascular Large B-Cell Lymphoma (IVLBCL)
- Geriatric Prognostic Index (GPI) of Isaksen et al for an Older Adult with Diffuse Large B-Cell lymphoma (DLBCL)
- Prognostic Factors of Vlatka et al for a Patient with Diffuse Large B-Cell Lymphoma (DLBCL)
- Models of Zhu et al for Predicting Survival of a Patient with Diffuse Large B-Cell Lymphoma (DLBCL): Nomogram
- Models of Zhu et al for Predicting Survival of a Patient with Diffuse Large B-Cell Lymphoma (DLBCL): Immune Risk Score
- Polycythemia Rubra Vera and Chorea
- Short-Term Ruxolitinib Prognostic Model (STR-PM) of Palandri et al for Ruxolitinib Discontinuation and Death in a Patient with Myelofibrosis
- MYSEC-PM Score of Passamonti et al for Myelofibrosis Post Polycythemia or Post Essential Thrombocythemia
- Predictive Model of Kekovic et al for Differentiating Prefibrotic Primary Myelofibrosis (prePMF) from Essential Thrombocythemia
- Cutaneous T-Cell Lymphoma (CTCL), the CTCL Severity Index and 5-Year Survival
- Decision Tree of Liu et al for Prognosis in a Patient with T-Cell Large Granular Lymphocytic Leukemia (LGLL)
- AML Risk Stratification Based on Genetics from the 2017 European LeukemiaNet (ELN)